Moreover, we observed that CDK4/6 inhibition represses a cancer cell programme shown to mediate resistance to anti‐PD1 therapy in melanoma, consistent with studies demonstrating a cooperation between CDK4/6i and immune checkpoint blockade [66, 132]. Here, CDK4 is linked to cancer.